GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:EGTX) » Definitions » Cyclically Adjusted PS Ratio

Egetis Therapeutics AB (OSTO:EGTX) Cyclically Adjusted PS Ratio : 10.77 (As of May. 19, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Egetis Therapeutics AB Cyclically Adjusted PS Ratio?

As of today (2024-05-19), Egetis Therapeutics AB's current share price is kr7.00. Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr0.65. Egetis Therapeutics AB's Cyclically Adjusted PS Ratio for today is 10.77.

The historical rank and industry rank for Egetis Therapeutics AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:EGTX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.3   Med: 7.53   Max: 27.37
Current: 10.84

During the past years, Egetis Therapeutics AB's highest Cyclically Adjusted PS Ratio was 27.37. The lowest was 4.30. And the median was 7.53.

OSTO:EGTX's Cyclically Adjusted PS Ratio is ranked worse than
66.86% of 510 companies
in the Biotechnology industry
Industry Median: 5.555 vs OSTO:EGTX: 10.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Egetis Therapeutics AB's adjusted revenue per share data for the three months ended in Mar. 2024 was kr0.041. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr0.65 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Egetis Therapeutics AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Cyclically Adjusted PS Ratio Chart

Egetis Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.31 9.25 8.21 9.96 8.42

Egetis Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.49 6.34 6.79 8.42 10.35

Competitive Comparison of Egetis Therapeutics AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PS Ratio falls into.



Egetis Therapeutics AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Egetis Therapeutics AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=7.00/0.65
=10.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Egetis Therapeutics AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.041/132.2054*132.2054
=0.041

Current CPI (Mar. 2024) = 132.2054.

Egetis Therapeutics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.432 0.000
201409 0.000 100.161 0.000
201412 0.000 100.225 0.000
201503 0.000 99.950 0.000
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.003 102.752 0.004
201709 0.000 103.279 0.000
201712 0.252 103.793 0.321
201803 0.014 103.962 0.018
201806 0.180 104.875 0.227
201809 0.125 105.679 0.156
201812 0.206 105.912 0.257
201903 1.020 105.886 1.274
201906 0.079 106.742 0.098
201909 0.104 107.214 0.128
201912 0.359 107.766 0.440
202003 0.201 106.563 0.249
202006 0.368 107.498 0.453
202009 0.044 107.635 0.054
202012 0.027 108.296 0.033
202103 0.021 108.360 0.026
202106 0.139 108.928 0.169
202109 0.034 110.338 0.041
202112 0.018 112.486 0.021
202203 0.039 114.825 0.045
202206 0.024 118.384 0.027
202209 0.024 122.296 0.026
202212 0.034 126.365 0.036
202303 0.028 127.042 0.029
202306 0.023 129.407 0.023
202309 0.049 130.224 0.050
202312 0.112 131.912 0.112
202403 0.041 132.205 0.041

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Egetis Therapeutics AB  (OSTO:EGTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Egetis Therapeutics AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB (OSTO:EGTX) Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB (OSTO:EGTX) Headlines

No Headlines